Health-related Quality of Life in the Phase III LUME-Colon 1 Study : Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses
Lenz, Heinz Joseph (Division of Medical Oncology. USC Norris Comprehensive Cancer Center)
Argilés Martínez, Guillem (Vall d'Hebron Institut d'Oncologia)
Yoshino, Takayuki (Department of Gastroenterology and Gastrointestinal Oncology. National Cancer Center Hospital East)
Lonardi, Sara (Phase 1 Trial Unit and Medical Oncology Unit 1. Istituto Oncologico Veneto IRCCS)
Falcone, Alfredo (Department of Oncology. University of Pisa)
Limón, María Luisa (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Sobrero, Alberto (Ospedale Policlinico San Martino IRCCS)
Hastedt, Claudia (Boehringer Ingelheim International GmbH)
Peil, Barbara (Boehringer Ingelheim Pharma GmbH & Co. KG)
Voss, Florian (Boehringer Ingelheim Pharma GmbH & Co. KG)
Griebsch, Ingolf (Boehringer Ingelheim International GmbH)
Van Cutsem, Eric (University Hospitals Leuven (Bèlgica))
Universitat Autònoma de Barcelona

Date:	2019
Abstract:	Based on European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) outputs from the LUME-Colon 1 study, we compared and discussed different statistical methods for evaluating health-related quality of life data in oncology clinical trials. The different analyses consistently showed that patients' overall global health status/quality of life status was not impaired by active treatment with nintedanib versus placebo, and that patients perceived some benefits with nintedanib compared with placebo.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	HRQoL ; MMRM ; Nintedanib ; QoL ; Time to deterioration
Published in:	Clinical Colorectal Cancer, Vol. 18 Núm. 4 (december 2019) , p. 269-279.e5, ISSN 1938-0674

DOI: 10.1016/j.clcc.2019.08.005
PMID: 31628043

16 p, 1.5 MB

The record appears in these collections:
Articles > Research articles
Articles > Published articles